00:47 , Feb 16, 2019 |  BC Extra  |  Company News

Management tracks: Nimbus, Ascentage, Cadent, Skyhawk

Computational biology company Nimbus Therapeutics LLC (Cambridge, Mass.) hired Peter Tummino as CSO. He was VP and global head of lead discovery at the Janssen Pharmaceuticals Inc. unit of Johnson & Johnson (NYSE:JNJ). Nimbus’ previous...
04:17 , Dec 8, 2017 |  BC Week In Review  |  Financial News

Atox Bio raises $30M series F

On Dec. 4, Atox Bio Ltd. (Ness Ziona, Israel) raised $30 million in a series F round led by new investor Arix Bioscience plc (LSE:ARIX), which contributed $8 million. Fellow new investors Adams Street Partners...
19:35 , Dec 4, 2017 |  BC Extra  |  Financial News

Atox Bio raises $30M series F

Atox Bio Ltd. (Ness Ziona, Israel) raised $30 million in a series F round led by new investor Arix Bioscience plc (LSE:ARIX), which contributed $8 million. Fellow new investors Adams Street Partners and Asahi Kasei...
03:15 , Jun 9, 2017 |  BC Week In Review  |  Clinical News

Reltecimod passes futility analysis in Phase III

Atox Bio Inc. (Ness Ziona, Israel) said an IDMC recommended continuation of the Phase III ACCUTE trial of reltecimod (AB103) to treat necrotizing soft tissue infections (NSTIs) in about 290 patients. The prespecified futility analysis...
23:56 , Nov 2, 2016 |  BC Innovations  |  Distillery Therapeutics

Infectious disease; inflammation

INDICATION: Sepsis; inflammation Cell culture and mouse studies identified CD86 -derived peptide mimetics that could help treat inflammation association with bacterial sepsis. Chemical synthesis and testing in a bacterial antigen-treated human liver cell line of...
07:00 , Jun 20, 2016 |  BC Week In Review  |  Company News

Atox Bio, U.S. Department of Health and Human Services infectious news

HHS’s Biomedical Advanced Research and Development Authority (BARDA) exercised an option under a 2014 contract with Atox to develop AB103 to treat necrotizing soft tissue infections. The option brings BARDA’s commitment to $17.4 million; the...
08:00 , Jan 4, 2016 |  BC Week In Review  |  Clinical News

AB103: Phase III started

Atox began the double-blind, placebo-controlled, U.S. Phase III ACCUTE trial to evaluate single doses of 0.5 mg/kg IV AB103 during or after surgical debridement plus the standard of care (SOC) in about 290 patients. Atox...
07:00 , Aug 18, 2014 |  BC Week In Review  |  Clinical News

AB103 regulatory update

Atox Bio said the European Commission granted Orphan Drug designation to AB103 to treat necrotizing soft tissue infections. The short peptide that modulates CD28 has completed Phase II testing to treat necrotizing soft tissue infections...
07:00 , Jul 28, 2014 |  BC Week In Review  |  Financial News

Atox Bio completes venture financing

Atox Bio Inc. , Ness Ziona, Israel   Business: Infectious, Autoimmune   Date completed: 2014-07-24   Type: Venture financing   Raised: Not disclosed   Investors: SR One; Lundbeckfond Ventures; OrbiMed Advisors   Note: Atox raised...
23:55 , Jul 24, 2014 |  BC Extra  |  Financial News

Atox Bio closes $23 million in E round

Infectious disease play Atox Bio Inc. (Ness Ziona, Israel) raised an undisclosed amount in the first tranche of a $23 million series E round led by new investor SR One. New investors Lundbeckfond Ventures and...